Acadia Pharmaceuticals (ACAD) Stock: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$27.83
0.09 (0.32%)
▲
5d:
-0.11%
30d:
-5.5%
90d:
+30.11%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 8, 2026 at $28.00 · last confirmed Sep 8, 2026
Strength: 5.7/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ACAD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ACAD shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.33
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $27.83, which is considered oversold relative to its 30-day fair value range of $27.80 to $29.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.2) compared to its historical average (28.2). At these levels, the market is pricing in 3.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is currently testing key support at $27.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACAD scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.00 (+22.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is currently testing key support at $27.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACAD scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.00 (+22.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$27.80 -
$29.87
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding ACAD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.6% below Wall St target ($34.00)
- NEUTRAL: Market pricing in 3.4% annual earnings growth - fairly valued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$27.80 -
$29.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$27.10
Resistance Level
$29.75
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.17
Wall Street Target
$34.00
(+22.6%)
Revenue Growth (YoY)
16.4%
Earnings Growth (YoY)
13.3%
Profit Margin
33.4%
Valuation Premium vs History
+3.4% premium
PE vs Historical
31.2 vs 28.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.4%
(market-implied from PE analysis)
1-Year Target
$28.68
(+3%)
2-Year Target
$29.66
(+7%)
3-Year Target
$30.67
(+11%)
3-Yr Target (if PE normalizes)
(PE: 31→28)
PE COMPRESSION
$27.75
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.2, Growth: 48.5%)
$90.85
(+228%)
Base:
(SPY PE: 20.2, Growth: 48.5%)
$58.79
(+112%)
Bear:
(PE: 17.1, Growth: 48.5%)
$49.97
(+80%)
📈
Valuation based on Current Earnings
Trailing PE: 12.36 | Current EPS (TTM): $2.24
Bull Case
$15.22
(-45%)
Analyst growth -50.0%, PE expands to 13.6
Base Case
$13.84
(-50%)
Market implied -50.0%, PE stable at 12.4
Bear Case
$18.82
(-32%)
Severe decline -20.0%, PE contracts to 10.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
